Advertisement

Protein Kinase A: The Enzyme and Cyclic AMP Signaling

  • Maria Nesterova
  • Constantine A. Stratakis
Chapter
Part of the Protein Reviews book series (PRON, volume 13)

Abstract

The main target of cAMP action in the cell is cAMP-dependent protein kinase (PKA) which exists mainly as two different isozymes, designated as type I (PKA-I) and type II (PKA-II) (more isozymes may exist). The two isoforms are distinct in their physico-chemical properties; the unexpectedly great differences between two isoforms of the same kinase that are both under tight control by the cAMP molecule point to an isozyme-specific involvement of PKA in cell functions. The relative ratio of PKA-I and PKA-II varies not only throughout the cell cycle in cells of the same type, but also among cells of the same tissue, and depends on developmental and differentiation stages. The balance of expression between PKA-I and PKA-II possibly plays a critical role as a sensitive regulator of cell growth, proliferation, and differentiation. Inactivating mutations of the gene coding for PKA-I regulatory subunit RIα (PRKAR1A) were found in a human disease (Carney Complex) that is linked to an inherited predisposition to a variety of largely benign and few malignant tumors; this finding further strengthened the notion that the holoenzyme’s function is critical for cellular growth and proliferation in at least the cAMP-responsive tissues. Thus, PKA has also emerged as a possible therapeutic target; its activity can be modulated with analogs of cAMP, oligonucleotides (antisense, transcription decoy oligonucleotide) and other agents targeting protein partners in signaling pathways. The first results of experiments with PKA modulators encouraged researchers to investigate further a new approach to therapy in the treatment of diseases using relatively nontoxic agents that are able to restore the natural balance of proliferation and differentiation in cells.

Keywords

Catalytic Subunit Chronic Myelogenous Leukemia Carney Complex Primary Pigment Nodular Adrenocortical Disease Primary Pigment Nodular Adrenocortical Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported by NICHD, NIH intramural project Z01-HD-000642-04 to Dr. C.A. Stratakis.

References

  1. Agrawal, S., Jiang, Z., Zhao Q, et al. (1997). Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 94:2620–2625.PubMedGoogle Scholar
  2. Ally, S., Tortora, G., Clair, T., et al. (1988). Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3′,5′-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. Proc. Natl. Acad. Sci. U.S.A. 85:6319–6322.PubMedGoogle Scholar
  3. Amieux, P.S., Cummings, D.E., Motamed, K., et al. (1997). Compensatory regulation of RI alpha protein levels in protein kinase A mutant mice. J. Biol. Chem. 272:3993–3998.PubMedGoogle Scholar
  4. Beebe, S.J., and Corbin, J.D. (1986). Cyclic nucleotide-dependent protein kinases. In: Boyer, P.D., Krebs, E.G. (eds) The Enzymes: Control by Phosphorylation, Part A, vol 17. Academic Press, New York pp. 43–111.Google Scholar
  5. Beebe, S.J., Øyen, O., Sandberg, M., et al. (1990). Molecular cloning of tissue-specific protein kinase (Cγ) from human testis representing a third isoform for the catalytic subunit of cAMP-dependent protein kinase. Mol. Endocrinol. 4:465–475.PubMedGoogle Scholar
  6. Beebe, S.J., Salomonsky, T., Jahnsen, T., et al. (1992). The C gamma subunit is a unique isozyme of the cAMP-dependent protein kinase. J. Biol. Chem. 267:25505–25512.PubMedGoogle Scholar
  7. Beene, D.L., and Scott, J.D. (2007). A-kinase anchoring proteins take shape. Curr. Opin. Cell Biol. 19:192–198.PubMedGoogle Scholar
  8. Blaschke, R.J., Monaghan, P., Bock, D., et al. (2000). A novel murine PKA-related protein kinase involved in neuronal differentiation. Genomics 64:187–194.PubMedGoogle Scholar
  9. Brandon, E.P., Logue, S.F., Adams, M.R., et al. (1998). Defective motor behavior and neural gene expression in RIIbeta-protein kinase A mutant mice. J. Neurosci. 18:3639–3649.PubMedGoogle Scholar
  10. Bryn, T., Mahic, M., Aandahl, E.M., et al. (2008). Inhibition of protein kinase A improves effector function of monocytes from HIV-infected patients. AIDS Res. Hum. Retrov. 24:1013–1015.PubMedGoogle Scholar
  11. Burton, K.A., Johnson, B.D., Hausken, Z.E., et al. (1997). Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 94:11067–11072.PubMedGoogle Scholar
  12. Burton, K.A., Treash-Osio, B., Muller, C.H., et al. (1999). Deletion of type II alpha regulatory subunit delocalizes protein kinase A in mouse sperm without affecting motility or fertilization. J. Biol. Chem. 274:24131–24136.PubMedGoogle Scholar
  13. Carlson, C.R., Witczak, O., Vossebein, L., et al. (2001). CDK1-mediated phosphorylation of the RIIα regulatory subunit of PKA works as a molecular switch that promotes dissociation of RIIα from centrosomes at mitosis. J. Cell Sci. 114:3243–3254.PubMedGoogle Scholar
  14. Chaturverdi, D., Poppleton, H.M., Stringfield, T., et al. (2006). Subcellular localization and biological actions of activated RSK1 are determined by its interactions with subunits of cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 26:4586–4600.Google Scholar
  15. Cheadle, C., Nesterova, M., Watkins, T., et al. (2008). Regulatory subunits of PKA define an axis of cellular proliferation/differentiation in ovarian cancer cells. BMC Med. Genomics 1:1–14.Google Scholar
  16. Cheley, S., and Bayley, H. (1991). Kinetics and regulation of two catalytic subunits of cAMP-dependent protein kinase from Aplysia californica. Biochemistry 30:10246–10255.PubMedGoogle Scholar
  17. Chen, H.X., Marshall, J.L., Ness, E., et al. (2000). A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM 231) targeting the type I protein kinase A by 2-hour infusions in patients with refractory solid tumors. Clin. Cancer Res. 6:1259–1266.PubMedGoogle Scholar
  18. Cheng, X., Phelps, C., Taylor, S. (2001). Differential binding of cAMP-dependent protein kinase regulatory subunit isoforms Iα and IIβ to the catalytic subunit. J. Biol. Chem. 276:4102–4108PubMedGoogle Scholar
  19. Cho, Y.S., Kim, M.K., Cheadle, C., et al. (2001). Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl. Acad. Sci. U.S.A. 98:9819–9823.PubMedGoogle Scholar
  20. Cho, Y.S., Kim, M.K., Cheadle, C., et al. (2002). A genomic-scale view of the cAMP response element-enhancer decoy: a tumor target-based genetic tool. Proc. Natl. Acad. Sci. U.S.A. 99:15626–15631.PubMedGoogle Scholar
  21. Cho-Chung, Y.S. (1979). On the interaction of cyclic AMP-binding protein and estrogen receptor in growth control. Life Sci. 24:1231–1240.PubMedGoogle Scholar
  22. Cho-Chung, Y.S. (1989). Site-selective 8-chloro-cyclic adenosine 3′, 5′-monophosphate as a biologic modulator of cancer: restoration of normal control mechanisms. J. Natl. Cancer Inst. 81:982–987.PubMedGoogle Scholar
  23. Cho-Chung, Y.S. (1990). Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy new approaches to therapy. Cancer Res. 50:7093–7100.PubMedGoogle Scholar
  24. Cho-Chung, Y.S., Clair, T., Tortora, G., et al. (1991). Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol. Ther. 50:1–33.PubMedGoogle Scholar
  25. Ciardiello, F. and Tortora, G. (1998). Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin. Cancer Res. 4:821–828.PubMedGoogle Scholar
  26. Ciardiello, F., Pepe, S., Bianco. C., et al. (1993). Down-regulation of RIα subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int. J. Cancer 53:438–443.PubMedGoogle Scholar
  27. Clegg, C.H., Cadd, G.G., McKnight, G.S. (1988). Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 85:3703–3707.PubMedGoogle Scholar
  28. Colledge, M., and Scott, J.D. (1999). Akaps: from structure to function. Trends Cell Biol. 9:216–221.PubMedGoogle Scholar
  29. Conkright, M.D., Guzmán, E., Flechner, L., et al. (2003). Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Mol. Cell 11:1101–1108.PubMedGoogle Scholar
  30. Constantinescu, A., Wu, M., Asher, O., et al. (2004). cAMP-dependent protein kinase type I regulates ethanol-induced cAMP response element-mediated gene expression via activation of CREB-binding protein and inhibition of MAPK. J. Biol. Chem. 279:43321–43329.PubMedGoogle Scholar
  31. Corbin,.J.D, Keely, S.L., Park, C.R. (1975). The distribution and dissociation of cyclic adenosine 3′, 5′-monophosphate-dependent protein kinases in adipose, cardiac and other tissues. J. Biol. Chem. 250:218–225.PubMedGoogle Scholar
  32. Cummings, D.E., Brandon, E.P., Planas, J.V., et al. (1996). Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A. Nature 382:622–626.PubMedGoogle Scholar
  33. Dell’Acqua, M.L., Smith, K.E., Gorski, J., et al. (2006). Regulation of neuronal PKA signaling through AKAP targeting dynamics. Eur. J. Cell Biol. 85:627–633.PubMedGoogle Scholar
  34. Di Isernia, G., Ciardiello, F., Sandomenico, C., et al. (1996). 8-Chloro-cAMP enhances the growth-inhibitory effect of cytotoxic drugs in human colon cancer cells. Int. J. Oncol. 9:1233–1237.Google Scholar
  35. Døskeland, S.O. (1978). Evidence that rabbit muscle protein kinase has two kinetically distinct binding sites for adenosine 3′, 5′-cyclic monophosphate. Biochem. Biophys. Res. Commun. 83:542–549.PubMedGoogle Scholar
  36. Dostman, W.R., Taylor, S.S., Genieser, H.G., et al. (1990). Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinase I and II with analogs of adenosine 3′, 5′-cyclicphosphorothioates. J. Biol. Chem. 265:10484–10491.Google Scholar
  37. Droogmans, L., Cludts, I., Cleuter, Y., et al. (1992). Nucleotide sequence of the bovine interleukine-6 gene promoter. DNA Seq. 3:115–117.PubMedGoogle Scholar
  38. Einzig, A.I., Wiernik, P.H., Sasloff, J. (1992). Phase II study and long term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10:1748–1753.PubMedGoogle Scholar
  39. Feliciello, A., Giuliano, P., Porcellini, A., et al. (1996). The v-Ki-Ras oncogene alters cAMP nuclear signaling by regulating the location and the expression of cAMP-dependent protein kinase IIbeta. J. Biol. Chem. 271:25350–25359.PubMedGoogle Scholar
  40. Fossberg, T.M., Doskeland, S.O., Ueland, P.M. (1978). Protein kinases in human renal cell carcinoma and renal cortex. A comparison of isozyme distribution and of responsiveness to adenosine 3′, 5′-cyclic monophosphate. Arch. Biochem. Biophys. 189:372–381.Google Scholar
  41. Gamm, D.M., Baude, E.J., Uhler, M.D. (1996). The major catalytic subunit isoforms of cAMP-dependent protein kinase have distinct biochemical properties in vitro and in vivo. J. Biol. Chem. 271:15736–15742.PubMedGoogle Scholar
  42. Gonzalez, G.A., and Montminy, M.R. (1989). Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59:675–680.PubMedGoogle Scholar
  43. Greene, E.L., Horvath, A.D., Nesterova, M., et al. (2008). In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay. Hum. Mut. 29:633–639.PubMedGoogle Scholar
  44. Griffin, K.J., Kirschner, L.S., Matyakhina, L., et al. (2004a). Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res. 64:8811–8815.PubMedGoogle Scholar
  45. Griffin, K.J., Kirschner, L.S., Matyakhina, L., et al. (2004b). A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J. Med. Genet. 41:923–931.PubMedGoogle Scholar
  46. Groussin, L., Kirschner, L.S., Vincent-Dejean, C., et al. (2002). Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am. J. Hum. Genet. 71:1433–1442.PubMedGoogle Scholar
  47. Gupte, R.S., Weng, Y., Liu, L., et al. (2005). The second subunit of the replication factor C complex (RFC40) and the regulatory subunit (RIalpha) of protein kinase A form a protein complex promoting cell survival. Cell Cycle 4:323–329.PubMedGoogle Scholar
  48. Handschin, J.C., Handloser, K., Takahashi, A., et al. (1983). Cyclic adenosine 3′, 5′-monophosphate receptor proteins in dysplastic and neoplastic human breast tissue cytosol and their inverse relationship with estrogen receptors. Cancer Res. 43:2947–2954.PubMedGoogle Scholar
  49. Hanks, S.K., Qinn, A.M., Hunter, T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42–52.PubMedGoogle Scholar
  50. Herberg, F.W. and Taylor, S.S. (1993). Physiological inhibitors of the catalytic subunit of cAMP-dependent protein kinase: effect of MgATP on protein-protein interactions. Biochemistry 32:14015–14022.PubMedGoogle Scholar
  51. Hoffmann, C., Raffel, S., Ruchaud, S., et al. (1996). Chloro-substituted cAMP analogues and their adenosine metabolites induce apoptosis of the human promyelocytic leukaemia cell line NB4: molecular basis for cell type selectivity. Cell. Pharmacol. 3:417–427.Google Scholar
  52. Hofman, F., Bechtel, P.J., Krebs, E.G. (1977). Concentrations of cyclic AMP-dependent protein kinase subunits in various tissues. J. Biol. Chem. 252:1441–1447.Google Scholar
  53. Horvath, A., Bossis, I., Giatzakis, C., et al. (2008). Large deletions of the PRKAR1A gene in Carney complex. Clin. Cancer Res. 14:388–395.PubMedGoogle Scholar
  54. Huggenvik, J.I., Collard, M.W., Stofko, R.E., et al. (1991). Regulation of the human enkephalin promoter by two isoforms of the catalytic subunit of cyclic adenosine 3′, 5′-monophosphate-dependent protein kinase. Mol. Endocrinol. 5:921–930.PubMedGoogle Scholar
  55. Imazumi-Scherrer, T., Faust, D.M., Barradeau, S. et al. (2001). Type I protein kinase A is localized to interphase microtubules and strongly associated with the mitotic spindle. Exp. Cell Res. 264:250–265.Google Scholar
  56. Jahnsen, T., Hedin, L., Kidd, V.J., et al. (1986). Molecular cloning, cDNA structure and regulation of the regulatory subunit of type II cAMP-dependent protein kinase from rat ovarian granulose cells. J. Biol. Chem. 261:12352–12361.PubMedGoogle Scholar
  57. Jarnaess, E., Ruppelt, A., Stokka, A.J., et al. (2008). Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J. Biol. Chem. 283:33708–33718.PubMedGoogle Scholar
  58. Jones, G.N., Tep, C., Towns, W.H. 2nd, et al. (2008). Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. Neoplasia 10:1213–1221.PubMedGoogle Scholar
  59. Khan, I.U., Laxminarayana, D., Kammer, G.M. (2001). Protein kinase A RI beta subunit deficiency in lupus T lymphocytes: bypassing a block in RI beta translation reconstitutes protein kinase A activity and augments IL-2 production. J. Immunol. 166:600–7605.PubMedGoogle Scholar
  60. Kim, S.N., Kim, S.G., Park, J.H., et al. (2000). Dual anticancer activity of 8-Cl-cAMP: inhibition of cell proliferation and induction of apoptotic cell death (2000). Biochem. Biophys. Res. Commun. 73:404–410.Google Scholar
  61. Kirschner, L.S., Carney, J.A., Pack, S.D. et al. (2000). Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat. Genet. 26:89–92.PubMedGoogle Scholar
  62. Kirschner, L.S., Kusewitt, D.F., Matyakhina, L., et al. (2005). A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res. 65:4506–4514.PubMedGoogle Scholar
  63. Klink, A., Schiebel, K., Winkelmann, M., et al. (1995). The human protein kinase gene PKX1 on Xp22.3 displays Xp/Yp homology and is a site of chromosomal instability. Hum. Mol. Genet. 4:869–878.PubMedGoogle Scholar
  64. Kondrashin, A.A., Nesterova, M.V., Cho-Chung, Y.S. (1998). Subcellular distribution of the R-subunits of cAMP-dependent protein kinase in LS-174T human colon carcinoma cells. Biochem. Mol. Biol. Intern. 45:237–244.PubMedGoogle Scholar
  65. Krett, N.L., Zell, J.L., Halgren, R.G., et al. (1997). Cyclic adenosine-3′, 5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin. Cancer Res. 3:1781–1787.PubMedGoogle Scholar
  66. Kuo, G.F., and Greengard, P. (1969). Cyclic nucleotide-dependent protein kinases. IV. Widespread occurrence of adenosine 3′, 5′-monophosphate-dependent protein kinase in various tissues and phyla of the animal kigdom. Proc. Natl. Acad. Sci. U.S.A. 64:1349–1355.PubMedGoogle Scholar
  67. Lange-Carter, C.A., and Malkinson, A.M. (1991). Alterations in the cAMP signal transduction pathway in mouse lung tumoriginesis. Exp. Lung Res. 17:341–357.PubMedGoogle Scholar
  68. Lania, A.G., Montovani, G., Ferrero, S., et al. (2004). Proliferation of transformed somatotroph cells related tp low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res. 64:9193–9198.PubMedGoogle Scholar
  69. Laxminarayana, D., and Kammer G.M. (2000). mRNA mutations of type I protein kinase A regulatory subunit alpha in T lymphocytes of a subject with systemic lupus erythematosus. Int. Immunol. 12:1521–1529.PubMedGoogle Scholar
  70. Lee, D.C., Carmichael, D.F., Krebs, E.G., et al. (1983). Isolation of a cDNA clone for the type I regulatory subunit of bovine cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 80:3608–3612.PubMedGoogle Scholar
  71. Levy, F.O., Øyen, O., Sandberg, M., et al. (1988). Molecular cloning, complementary deoxyribonucleic acid structure and predicted full-length amino acid sequence of the hormone-inducible regulatory subunit of 3′, 5′-cyclic adenosine monophosphate-dependent protein kinase from human testis. Mol. Endocrinol. 2:1364–1373.PubMedGoogle Scholar
  72. Liu, W.M., Scott, K.A., Shahin, S., et al. (2004). The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. Eur. J. Biochem. 271:2773–2781.PubMedGoogle Scholar
  73. Liu, J., Rone, M.B., Papadopoulos, V. (2006). Protein-protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis. J. Biol. Chem. 281:38879–38893.PubMedGoogle Scholar
  74. Lygren, B., and Tasken, K. (2008). The potential use of AKAP18δ as a drug target in heart failure patients. Expert Opin. Biol. Ther. 8:1099–1108.PubMedGoogle Scholar
  75. Mavrakis, M., Lippincott-Schwartz, J., Stratakis, C.A., et al. (2006). Depletion of type IA regulatory subunit (RIα) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency. Hum. Mol. Genet. 15:2962–2971.PubMedGoogle Scholar
  76. Mavrakis, M., Lippincott-Schwartz, J., Stratakis, C.A., et al. (2007). mTOR kinase and the regulatory subunit of protein kinase A (PRKAR1A) spatially and functionally interact during autophagosome maturation. Autophagy 3:151–153.PubMedGoogle Scholar
  77. Mayr, B., and Montminy, M. (2001). Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell. Biol. 2:599–609.PubMedGoogle Scholar
  78. McDaid, H.M., and Johnston, P.G. (1999). Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′, 5′-monophosphate in human ovarian carcinoma cell lines. Clin. Cancer Res. 5:215–220.PubMedGoogle Scholar
  79. McKnight, G.S., Idzerda, R.L., Kandel, E.R., et al. (1996). Targeted disruption of the protein kinase A system in mice. In: Hansson, V., Levy, F.O., Tasken, K. (eds) Signal transduction in testicular cells. Basic and Clinical Aspects, vol 1. Springer-Verlag, Berlin, pp. 95–122.Google Scholar
  80. Mellon, P.L., Clegg, C.H., Correll, L.A. et al. (1989). Regulation of transcription by cyclic AMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 86:4887–4891.PubMedGoogle Scholar
  81. Meoli, E., Bossis, I., Cazabat, L. et al. (2008). Protein kinase A. Effects of an expressed PRKAR1A mutation associated with aggressive tumors. Cancer Res. 68:3133–3141.PubMedGoogle Scholar
  82. Metelev, V., Liszlewicz, J., Agrawal, S. (1994). Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′ O-methyloligoribonucleotides. Bioorg. Med. Chem. Lett. 4:2929–2934.Google Scholar
  83. Miller, W.R. (2002). Regulatory subunits of PKA and breast cancer. Ann. NY Acad. Sci. 968:37–48.PubMedGoogle Scholar
  84. Monia, B.P., Lesmik, E.A., Gonzalez, C., et al. (1993). Evaluation of 2′-modified oligonucleotides containing 2′-deoxygaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514–14522.PubMedGoogle Scholar
  85. Moriuchi, A., Ido, A., Nagata, Y. et al. (2003). A CRE and the region occupied by a protein induced by growth factor contribute to up-regulation of cyclin D1 expression in hepatocytes. Biochem. Biophys. Res. Commun. 300:415–421.PubMedGoogle Scholar
  86. Morris, R.C., Morris, G.Z., Zhang, W., et al. (2002). Differential transcriptional regulation by the alpha- and gamma-catalytic subunit isoforms of cAMP-dependent protein kinase. Arch. Biochem. Biophys. 403:219–228.PubMedGoogle Scholar
  87. Nadella, K.S., and Kirschner, L.S. 2005 Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res. 65:10307–10315.PubMedGoogle Scholar
  88. Nadella, K.S., Jones, G.N., Trimboli, A. et al. (2008). Targeted deletion of Prkar1a reveals a role for protein kinase A in mesenchymal-to-epithelial transition. Cancer Res. 68:2671–2677.PubMedGoogle Scholar
  89. Neary, C.L., and Cho-Chung, Y.S. (2001). Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RI alpha regulatory subunit. Oncogene 20:8019–8024.PubMedGoogle Scholar
  90. Neary, C.L., Nesterova, M., Cho, Y.S., et al. (2004). Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 23:8847–8856.PubMedGoogle Scholar
  91. Nestereova, M. and Cho-Chung, Y.S. (1995). A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nature Med. 1:528–533.Google Scholar
  92. Nesterova, M., Bossis, I., Wen, F., et al. (2008). An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type allele and other protein kinase A subunits. J. Clin. Endocrinol. Metab. 93:565–571.PubMedGoogle Scholar
  93. Noguchi, K., Murata, T., Cho-Chung, Y.S. (1998). 8-Chloradenosine 3′, 5′-monophosphate (8-Cl cAMP). Selectively eliminates protein kinase A type I to induce growth inhibition in c-ras.-transformed fi broblasts. Eur. J. Cancer 34:1260–1267.PubMedGoogle Scholar
  94. Øgreid, D., and Døskeland, S.O. (1980). Protein kinase II has two distinct binding sites for cyclic AMP, only one which is detectable by the conventional membrane filtration method. FEBS Lett. 121:340–344.PubMedGoogle Scholar
  95. Øgreid, D., Døskeland, S.O., Miller, J.P. (1983). Evidence that cyclic nucleotides activating rabbit muscle protein kinase I interact with both types of cAMP binding sites associated with the enzyme. J. Biol. Chem. 258:1041–1049.PubMedGoogle Scholar
  96. Øgreid, D., Ekanger, R., Suva, R.H., et al. (1985). Activation of protein kinase izosymes by cyclic nucleotide analogs used singly or in combination. Eur. J. Biochem. 150:219–227.PubMedGoogle Scholar
  97. Øyen, O., Myklebust, F., Scott, J.D., et al. (1989). Human testis cDNA for the regulatory subunit RIIα of cAMP-dependent protein kinase encodes an alternate amino-terminal region. FEBS Lett. 246:57–64.PubMedGoogle Scholar
  98. Park, Y.G., Nesterova, M., Agrawal, S., et al. (1999). Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription gfactor decoy oligonucleotide. Gene-specific inhibition of tumor growth. J. Biol. Chem. 274:1573–1580.PubMedGoogle Scholar
  99. Park, Y.G., Park, S., Lim, S.O., et al. (2001). Reduction in cyclin D1/Sdk4/retinoblastoma protein signaling by CRE-decoy oligonucleotide. Biochem. Biophys. Res. Commun. 281:1213–1219.PubMedGoogle Scholar
  100. Pastan, I., Johnson, G.S., Anderson, W.B. (1975). Role of cyclic nucleotides in growth control. Annu. Rev. Biochem. 44:491–522.PubMedGoogle Scholar
  101. Pavel, E., Nadella, K., Towns, W.H. 2nd, Kirschner, L.S. (2008). Mutation of Prkar1a causes osteoblast neoplasia driven by dysregulation of protein kinase A. Mol. Endocrinol. 22:430–440.PubMedGoogle Scholar
  102. Planas, J.V., Cummings, D.E., Idzerda, R.L., et al. (1999). Mutation of the RII beta subunit of protein kinase A differentially affects lipolysis but not gene induction in white adipose tissue. J. Biol. Chem. 274:36281–36287.PubMedGoogle Scholar
  103. Reinton, N., Haugen, T.B., Ørstavik, S., et al. (1998). The gene encoding the C gamma catalytic subunit of cAMP-dependent protein kinase is a transcribed retroposon. Genomics 49:290–297.PubMedGoogle Scholar
  104. Riabowol, K.T., Fink, J.S., Oilman, M.Z., et al. (1988). The catalytic subunit of cAMP-dependent protein kinase induces expression of genes containing cAMP-responsive enhancer elements. Nature 336:83–86.PubMedGoogle Scholar
  105. Robinson-Steiner, A.M., and Corbin, J. (1983). Probable involvement of both intrachain cAMP binding sites in activation of protein kinase. J. Biol. Chem. 259:1032–1040.Google Scholar
  106. Robinson-White, A., and Stratakis, C.A. (2002). Protein kinase A signaling: “cross-talk” with other pathways in endocrine cells. Ann. N Y Acad. Sci. 968:256–270.PubMedGoogle Scholar
  107. Robinson-White, A., Hundley, T.R., Shiferaw, M., et al. (2003). Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum. Mol. Genet. 12:1475–1484.PubMedGoogle Scholar
  108. Robinson-White, A.J., Leitner, W.W., Aleem, E., et al. (2006a). PRKAR1A inactivation leads to increased proliferation and decreased apoptosis in human B lymphocytes. Cancer Res. 66:10603–10612.PubMedGoogle Scholar
  109. Robinson-White, A., Meoli, E., Stergiopoulos, S., et al. (2006b). PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex. J. Clin. Endocrinol. Metab. 91 2380–2388.PubMedGoogle Scholar
  110. Robison, G.A. (1973). The biological role of cyclic AMP: an updated review. In: Kahn, RH., and Lands, W.E.M. (eds) Prostaglandins and Cyclic AMP: Biological Actions and Clinical Applications, Academic Press, New York, pp. 229–247.Google Scholar
  111. Rohlff, C., Clair, T., Cho-Chung, Y.S. (1993). 8-Cl-cAMP induces truncation and down-regulation of the RI α subunit and up-regulation of the RII β subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J. Biol. Chem. 268:5774–5782.PubMedGoogle Scholar
  112. Rosen, O.M., and Erlichman, J. (1975). Reversible autophosphorylation of a cyclic 3′, 5′-AMP-dependent protein kinase from bovine cardiac muscle. J. Biol. Chem. 250:7788–7794.PubMedGoogle Scholar
  113. Ruppelt, A., Mosenden, R., Gronholm, M. et al. (2007). Inhibition of T cell activation by cyclic adenosine 5 -monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein Ezrin1. J. Immunol. 179:5159–5168.PubMedGoogle Scholar
  114. Russell, D.L., Doyle, K.M., Gonzales-Robayna, I. et al. (2003). Egr-1 induction in rat granulose cells by follicle-stimulating hormone and luteinizing hormone: combinatorial regulation by transcription factors cyclic adenosine 3′, 5′-monophosphate regulatory element binding protein, serum response factor, sp1, and early growth response factor-1. Mol. Endocrinol. 17:520–533.PubMedGoogle Scholar
  115. Sandberg, M., Tasken, K., Øyen, O., et al. (1987). Molecular cloning, cADNA structure and deduced amino acid sequence for a type I regulatory subunit of cAMP-dependent protein kinase from human testis. Biochem. Biophys. Res. Commun. 149:939–945.PubMedGoogle Scholar
  116. Schreyer, S.A., Cummings, D.E., McKnight, G.S., et al. (2001). Mutation of the RII beta subunit of protein kinase A prevents diet-induced insulin resistance and dyslipidemia in mice. Diabetes 50:2555–2562.PubMedGoogle Scholar
  117. Schwede, F., Maronde, E., Genieser, H., et al. (2000). Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther. 87:199–226.PubMedGoogle Scholar
  118. Scott, J.D., Glaccum, M.B., Zoller, M.J. et al. (1987). The molecular cloning of a type II regulatory subunit of the cAMP-dependent protein kinase from rat skeletal muscle and mouse brain. Proc. Natl. Acad. Sci. U.S.A. 84:5192–5196.PubMedGoogle Scholar
  119. Shaywitz, A.J., and Greenberg, M.E. (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68:821–861.PubMedGoogle Scholar
  120. Sheppard, J.R. (1974). The role of cyclic AMP in the control of cell division. In: Braun, W., Lichtenstein, L.M., Parker, C.W. (eds.). Cyclic AMP, Cell Growth, and the Immune Response. Springer, Berlin, pp 290–301.Google Scholar
  121. Skalhegg, B.S., Landmark, B.F., Doskeland, S.O., et al. (1992). Cyclic AMP-dependent protein kinase type I mediates the inhibitory effect of 3′, 5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J. Biol. Chem. 267:15707–15714.PubMedGoogle Scholar
  122. Solberg, R., Tasken, K., Keiserud, A., et al. (1991). Molecular cloning, cDNA structure and tissue-specific expression of the human regulatory subunit RIβ of cAMP-dependent protein kinases. Biochem. Biophys. Res. Commun. 176:166–172.PubMedGoogle Scholar
  123. Solberg, R., Tasken, K., Wen, W., et al. (1994). Human regulatory subunit RIβ of cAMP-dependent protein kinases: expression, holoenzyme formation and microinjection into living cells. Exp. Cell Res. 214:595–605.PubMedGoogle Scholar
  124. Solberg, R., Sandberg, M., Natarajan, V., et al. (1997). The human gene for the regulatory subunit RIα of cAMP-dependent protein-kinase. Two distinct promoters provide differential regulation of alternately spliced mRNAs. Endocrinology 138:169–181.PubMedGoogle Scholar
  125. Srivastava, R.K., Srivastava, A.R., Cho-Chung, Y.S., et al. (1999). Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells. Oncogene 18:1755–1763.PubMedGoogle Scholar
  126. Stratakis, C.A. (2000). Genetics of Carney complex and related familial lentiginoses, and other multiple tumor syndromes. Front Biosci 5:353–366.Google Scholar
  127. Stratakis, C.A., Kirshner, L.S., Carney, J.A. (2001). Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 86:4041–4046.PubMedGoogle Scholar
  128. Tasken, K., Hansson, V., Aukrust, P., et al. (2000). PKAI as a potential target for therapeutic intervention. Drug News Perspect. 13:12–18.PubMedGoogle Scholar
  129. Taylor, S.S., Bubis, J., Toner-Webb, J., et al. (1988). cAMP-dependent protein kinase: prototype for a family of enzymes. FASEB J. 2:2677–2685.PubMedGoogle Scholar
  130. Taylor, S.S., Knighton, D.R., Zheng, J., et al. (1992). Structural framework for the protein kinase family. Annu. Rev.Cell Biol. 8:429–462.PubMedGoogle Scholar
  131. Titani, K., Sasagawa, T., Ericsson, L.H., et al. (1984). Amino acid sequence of the regulatory subunit of bovine type I cAMP-dependent protein kinase. Biochemistry 23:4193–4199.PubMedGoogle Scholar
  132. Tortora, G., and Ciardiello, F. (2002). Protein kinase A as target for novel integrated strategies of cancer therapy. In: Stratakis, C.A., Cho-Chung, Y.S. (eds) Protein Kinase A in human disease. Ann. NY Acad. Sci. 968:139–147.Google Scholar
  133. Tortora, G., Tagliaferri, P., Clair, T., et al. (1988). Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic and acute lymphocytic human leukaemia cell lines. Blood 71:230–233.PubMedGoogle Scholar
  134. Tortora, G., Yokozaki, H., Pepe, S., et al. (1991). Differentiation of HL-60 leukemia cells by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase Proc. Natl. Acad. Sci. U.S.A. 88:2011–2015.PubMedGoogle Scholar
  135. Tortora, G., Caputo, R., Damiano, V. et al. (1997a). Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 94:12586–12591.PubMedGoogle Scholar
  136. Tortora, G., Damiano, V., Bianco, C., et al. (1997b). The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor. Oncogene 14:923–928.PubMedGoogle Scholar
  137. Tortora, G., Di Isernia, G., Sandomenico, C., et al. (1997c). Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res. 57:5107–5111.PubMedGoogle Scholar
  138. Tortora, G., Bianco, C., Damiano, V. et al. (2000). Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin. Cancer Res. 6:2506–2512.PubMedGoogle Scholar
  139. Tortora, G., Caputo, R., Damiano, V. et al. (2001). Combined blockade of protein kinase A and Bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin. Cancer Res. 7:2537–2544.PubMedGoogle Scholar
  140. Uhler, M.D., Carmichael, D.M., Lee, D.C., et al. (1986a). Isolation of cDNA clones coding for the catalytic for the catalytic subunit of mouse cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 83:1300–1304.PubMedGoogle Scholar
  141. Uhler, M.D., Chrivia, J.C., McKnight, G.S. (1986b). Evidence for a second isoform of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. Chem. 261:15360–15363.PubMedGoogle Scholar
  142. Vigil, D., Blumenthal, D.K., Brown, S. et al. (2004). Differential effects of substrate on type I and type II PKA holoenzyme dissociation. Biochemistry 43:5629–5636.PubMedGoogle Scholar
  143. Vintermyr, O.K., Bøe, R., Brustugun, O.T., et al. (1995). Cyclic adenosine monophosphate (cAMP) analogs 8-Cl-cAMP and 8-NH2-cAMP induce cell death independently of cAMP kinase-mediated inhibition of the G1/S transition in mammary carcinoma cells (MCF-7). Endocrinology 136:2513–2520.PubMedGoogle Scholar
  144. Viste, K., Kopperud, R.K., Christensen, A.E., et al. (2005). Substrate enhances the sensitivity of type I protein kinase A to cAMP. J. Biol. Chem. 280:13279–13284.PubMedGoogle Scholar
  145. Wang, H., Hang, J., Shi, Z., et al. (2002). Antisense oligonucleotide targeted to RI alpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectivness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografs: in vivo synergistic activity, pharmacokinetics and host toxicity. Int. J. Oncol. 21:73–80.PubMedGoogle Scholar
  146. Weissinger, E.M., Oettrich, K., Evans, C., et al. (2004). Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy. Br. J. Cancer 91:186–192.PubMedGoogle Scholar
  147. Yang, W.L., Iacono, L., Tang, W.M., et al. (1998). A novel mechanism of cAMP signaling through the interaction of the regulatory subunit of protein kinase A with cytochrome c oxidase subunit Vb. Biochemistry 37:14175–14180.PubMedGoogle Scholar
  148. Yin, Z., Jones, G.N., Towns, W.H. 2nd, et al. (2008a). Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation. 117:414–1422.Google Scholar
  149. Yin, Z., Williams-Simons, L., Parlow, A.F. et al. (2008b). Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol. Endocrinol. 22:380–387.PubMedGoogle Scholar
  150. Yokozaki, H., Budillon, A., Tortora, G. et al. (1993). An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res. 53:868–872.PubMedGoogle Scholar
  151. Zawadzki, K.M. and Taylor, S.S. (2004). cAMP-dependent protein kinase regulatory subunit type II active site mutations define an isoform-specific network for allosteric signaling by cAMP. J. Biol. Chem. 20:7029–7036Google Scholar
  152. Zhang, W., Morris, G.Z., Beebe, J. (2004). Characterization of the cAMP-dependent protein kinase catalytic subunit Cγ expressed and purified from sf9 cells. Protein Expr. Purif. 35:156–169.PubMedGoogle Scholar
  153. Zhang, X., Odom, D.T., Koo, S.H., et al. (2005). Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. U.S.A. 102:4459–4464.PubMedGoogle Scholar
  154. Zimmermann, B., Chiorini, J.A., Ma, Y., et al. (1999). PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit Type I. J. Biol. Chem. 274:5370–5378.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Section on Endocrinology Genetics, Program on Developmental Endocrinology Genetics (PDEGEN), Eunice Kenney Shriver National Institute of Child Health & Human Development (NICHD)National Institute of Health (NIH)BethesdaUSA

Personalised recommendations